NCT00613626 - Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Small Cell Lung Cancer

Interventions

DRUG

Cisplatin

Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles

DRUG

Etoposide

Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles

DRUG

Placebo

Matched placebo oral daily

DRUG

ZD6474

ZD6474 100mg oral daily to be continued for the duration of the study.

Trial Locations (19)

19106

Pennsylvania Oncology-Hematology Associates, Philadelphia

19713

Helen F. Graham Cancer Center, Newark

46202

IN Onc/Hem Associates, Indianapolis

Indiana University Simon Cancer Center, Indianapolis

46206

St. Vincent Hospital & Health Centers, Indianapolis

46321

Monroe Medical Associates, Munster

46601

Northern Indiana Cancer Research Consortium, South Bend

46815

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

47303

IU Health at Ball Memorial Hospital, Muncie

47403

Cancer Care Center of Southern Indiana, Bloomington

47714

Oncology Hematology Associates of SW Indiana, Evansville

47802

Providence Medical Group, Terre Haute

47904

IU Health Arnett Cancer Center, Lafayette

47905

Horizon Oncology Researcg, Lafayette

60611

Northwestern University Feinberg School of Medicine, Chicago

61401

Medical & Surgical Specialists, LLC, Galesburg

68114

Methodist Cancer Center, Omaha

97213

Providence Portland Medical Center, Portland

08060

Hematology Oncology Associates S.J., P.A., Mount Holly